PDS Biotechnology Corporation

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PDS Biotechnology advances oncology pipeline with promising trial results

PDS Biotechnology's strategic focus on oncology pipeline advancement, strong interim trial results, and financial stability position the company for continued growth and clinical success.
While facing financial challenges and operational complexities, the company's proactive approach to trial designs, regulatory engagements, and commercialization strategies offer promising opportunities for future development.
Overall, PDS Biotechnology's performance in 2022 reflects a balance of achievements, challenges, and opportunities, underscoring a commitment to innovation and clinical progress in the oncology space.

PDS Biotechnology reports Q1 loss, progresses promising cancer therapies

PDS Biotechnology's Q1 performance reflects ongoing investment in clinical development.
Strengths lie in innovative therapies, upcoming Phase 3 trial, and manufacturing progress.
Challenges include financial losses, competition, and meeting trial milestones.
Opportunities exist in clinical advancements, partnerships, market demand, and investor confidence.

PDS Biotechnologies reports Q2 loss, progresses in clinical trials

PDS Biotechnologies faces increased expenses but maintains strong funding for future operations.
Progress in clinical programs and upcoming milestones provide growth opportunities.
Challenges include trial requirements and enrollment timelines, but company is managing well.

PDS Biotechnology reports promising cancer therapy results amidst financial challenges

PDS Biotechnology demonstrates clinical success with PDS0101 and PDS01ADC, while facing financial pressures and operational challenges.
Strategic strengths in oncology programs and proactive clinical development position the company for growth and potential partnerships.
Opportunities lie in diversification with PDS0202, expanding the pipeline, and leveraging positive data from upcoming investigator-initiated trials.
Navigating financial challenges, operational complexities, and maximizing therapeutic potential will be key for PDS Biotechnology's future success.

PDS Biotechnology reports Q4 loss, focuses on innovative cancer trials

PDS Biotechnology's Q4 2023 Earnings Call highlighted financial performance, strategic focus on innovative clinical trials, and promising data-driven decisions.
The company's strengths lie in its collaborations with the National Cancer Institute, advancements in Phase II programs, and a healthy cash balance supporting future funding.
Challenges include managing rising operating expenses, delivering on trial outcomes, and navigating market competition, while opportunities exist in establishing leadership in cancer therapies and attracting investors.
Overall, PDS Biotechnology's emphasis on data-driven strategies, strong financial position, and commitment to advancing cancer treatments position it for potential growth and success in the biopharmaceutical industry.

PDS Biotechnology reports Q3 loss, optimistic on Versamune HPV potential

PDS Biotechnology Corporation's Q3 2024 performance reflected increased R&D expenses and strategic trial design modifications.
Despite financial challenges and competitive pressures, the company remains optimistic about the potential of Versamune HPV.
Opportunities lie in advancing the VERSATILE-003 trial, leveraging positive feedback, and addressing unmet medical needs in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

FLORHAM PARK, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage cancer immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community on Wednesday, June 16th.

PDS Biotechnology Announces Oncology Research and Development Day

PDS Biotechnology Corp (NASDAQ:PDSB) shares are trading higher by 13.3% at $10.65 Tuesday morning after the company highlighted the release of interim data for PDS0101 in an NCI-led Phase 2 clinical study in oral presentation at the ASCO 2021 annual meeting. PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States.

Why PDSB Shares Are Trading Higher Today

NetScientific PLC (LON:NSCI) portfolio company, PDS Biotechnology (NASDAQ:PDSB) said a Phase 2 trial for an immunotherapy treatment for HPV cancer had indicated tumour regression. Presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, the data showed results of a phase PDS's candidate PDS0101 in combination with two immune-modulating agents on 25 patients.

NetScientific PLC on the rise aagain after PDS cancer trial

Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy Tumor reduction was observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve advanced cancer patients and 58% (7 of 12) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy

CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting

PDS Biotechnology Corporation (NASDAQ: PDSB) has announced interim data from the Phase 2 trial led by the National Cancer Institute (NCI) evaluating PDS0101 (Versamune-HPV16) in combination with two investigational immune-modulating agents - bintrafusp alfa and NHS-IL12 for HPV16 positive cancers. Data were presented at the American Society of Clinical Oncology 2021 Annual Meeting.

PDS Biotech's Lead Versamune Program Achieves Overall Tumor Reduction of 67% In HPV16 Positive Cancer Patients

PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting

PDSB has gained over 125% since clinical data in an ASCO abstract on its lead cancer therapeutic was published. The company still has lots of room for growth if its lead therapeutic candidate is eventually approved to treat HPV-associated cancers.

PDS Biotech Shines At The ASCO 2021 Annual Meeting

FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced the protocol amendment to expand its Phase 2 VERSATILE-002 study to include patients, in an additional arm, who have failed prior checkpoint inhibitor (CPI) therapy (CPI refractory patients). The VERSATILE-002 study is designed to evaluate PDS0101 in combination with KEYTRUDA® (pembrolizumab) in the treatment of advanced human papillomavirus (HPV)-associated head and neck cancer and is currently being run at approximately 20 clinical sites in the US.

PDS Biotechnology Expands VERSATILE-002 study of PDS0101 and KEYTRUDA® in Advanced Head and Neck Cancer to Include Patients Who Have Failed Prior Treatment with Checkpoint Inhibitors

FLORHAM PARK, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced it will host an Oncology R&D Day for analysts, investors, and the scientific community from 8:00 – 10:00 AM ET on Wednesday, June 16th.

PDS Biotech to Host Oncology R&D Day on June 16, 2021

Strategic partnership offers both organizations a way to share information about emerging treatment options with clinicians and patients battling HPV-attributed head and neck cancer Strategic partnership offers both organizations a way to share information about emerging treatment options with clinicians and patients battling HPV-attributed head and neck cancer

PDS Biotechnology Establishes Partnership With Head and Neck Cancer Alliance

Investors need to pay close attention to PDS Biotechnology (PDSB) stock based on the movements in the options market lately.

Implied Volatility Surging for PDS Biotechnology (PDSB) Stock Options

FLORHAM PARK, N.J., May 24, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company's proprietary Versamune® T-cell activating technology, today announced that they will host a company conference call on June 8, 2021 at 8:00 am ET, following the oral presentation of preliminary data of PDS0101 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. A press release summarizing the abstract data was issued on May 20.

PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting

The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by over 6% pre-market. This is why it happened.

PDSB Stock Price: Over 6% Increase Pre-Market Explanation

The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by 14.58% on Friday, May 21. This is why it happened.

PDSB Stock Price: 14.58% Increase Explanation

Infinity Pharma

CASI Pharmaceuticals

IsoRay

Savara

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10

NetScientific PLC (LON:NSCI) said an investee company will share additional data that will underline the potential efficacy of a breakthrough cancer immunotherapy. PDS Biotechnology Corporation (NASDAQ:PDSB) will use its presentation at the prestigious American Society of Clinical Oncology (ASCO) annual meeting next month to reveal it has observed a 10-out-of-14, or 71% response rate to lead drug PDS0101.

NetScientific hails the potential of investee company's cancer immunotherapy

The stock price of PDS Biotechnology Corp (NASDAQ: PDSB) increased by 26.66% today. This is why it happened.

PDS Biotechnology (PDSB) Stock: 26.66% Increase Explanation

Ardelyx

GT Biopharma Inc

Vaxart

Penny stocks that left the nest in 2021 To Watch Right Now The post Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021

PDS Biotechnology Corporation (NASDAQ: PDSB) has announced the publication of an abstract by the American Society of Clinical Oncology summarizing interim data from the National Cancer Institute (NCI)-led Phase 2 trial evaluating a combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ relapsed or refractory advanced cancer. Data will be presented at the 2021 ASCO Annual Meeting and is expected to include results from a larger sample than the 14 patients included in the abstract.

PDS Biotech's Triplet Therapy Shows Clinical Activity In Advanced HPV-Associated Malignancies

Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63% (5 of 8) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy Objective responses (tumor reduction) observed in 83% (5 of 6) of HPV16-positive relapsed or refractory checkpoint inhibitor naïve patients and 63% (5 of 8) of HPV16-positive relapsed or refractory advanced cancer patients who have also failed checkpoint inhibitor therapy

PDS Biotech Announces Release of Abstract for PDS0101 in NCI-Led Phase 2 Clinical Study for Oral Presentation at 2021 ASCO Meeting

Preeminent translational cancer immunotherapy researcher and renowned clinical/commercial cancer immunotherapy expert join the advisory board Preeminent translational cancer immunotherapy researcher and renowned clinical/commercial cancer immunotherapy expert join the advisory board

PDS Biotechnology Appoints Immuno-Oncology Experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board

NetScientific PLC (LON:NSCI) said its portfolio firm, PDS Biotechnology Corp (NASDAQ:PDSB), it which it owns a 5.75% stake, has received US$4.5mln from the net sale of tax benefits to an unrelated, profitable New Jersey corporation pursuant to the company's participation in the New Jersey Technology Business Tax Certificate Transfer Net Operating Loss (NOL) program for 2020. The NOL program enables qualified, unprofitable NJ-based technology or biotechnology companies with fewer than 225 U.

NetScientific portfolio firm PDS Biotech sells off New Jersey tax benefits

PDS Biotechnology Corp (PDSB) CEO Frank Bedu-Addo on Q1 2021 Results - Earnings Call Transcript

FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call today.

PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results

PDS Biotechnology Corporation (NASDAQ: PDSB) will be reporting preliminary Phase 2 clinical data of its lead compound PDS0101 for the treatment of advanced HPV-associated cancers in patients whose cancer has returned or progressed after treatment at the upcoming American Society of Clinical Oncology (ASCO) 2021 Annual Meeting on June 4-8.  The study is being performed under a collaboration agreement with the National Cancer Institute (NCI).

News for PDS Biotechnology Corporation Stock (PDSB)